About HLA class II histocompatibility antigen, DRB1 beta chain
HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DRB1) is a protein
from Homo sapiens identified by UniProt accession
P01911, 266 residues long.
MolForge cross-references it against 0 known binders and
836 disease associations.
Target properties
| Protein name | HLA class II histocompatibility antigen, DRB1 beta chain |
|---|
| UniProt accession | P01911 |
|---|
| Gene | HLA-DRB1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 266 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (836)
Diseases linked to this target (Open Targets).
- rheumatoid arthritis · score 0.42
- systemic lupus erythematosus · score 0.33
- breast adenocarcinoma · score 0.25
- Takayasu arteritis · score 0.23
- Crohn's disease · score 0.23
- ulcerative colitis · score 0.23
- narcolepsy-cataplexy syndrome · score 0.23
- Alzheimer disease · score 0.22
- family history of Alzheimer’s disease · score 0.21
- neurodegenerative disease · score 0.21
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P01911-F1 | alphafold | PREDICTED | 88.41 | — |
Amino-acid sequence (266 residues)
MVCLKLPGGS CMTALTVTLM VLSSPLALSG DTRPRFLWQP KRECHFFNGT ERVRFLDRYF YNQEESVRFD SDVGEFRAVT ELGRPDAEYW NSQKDILEQA RAAVDTYCRH NYGVVESFTV QRRVQPKVTV YPSKTQPLQH HNLLVCSVSG FYPGSIEVRW FLNGQEEKAG MVSTGLIQNG DWTFQTLVML ETVPRSGEVY TCQVEHPSVT SPLTVEWRAR SESAQSKMLS GVGGFVLGLL FLGAGLFIYF RNQKGHSGLQ PTGFLS
Explore HLA class II histocompatibility antigen, DRB1 beta chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets